Patents by Inventor Shawn David Erickson

Shawn David Erickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9896433
    Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: February 20, 2018
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Zhi Chen, Elbert Chin, Shawn David Erickson, Stephen Deems Gabriel, Eric Mertz, Robert James Weikert
  • Patent number: 9693997
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: July 4, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Feng Chi, Elbert Chin, Qingjie Ding, Shawn David Erickson, Stephen Deems Gabriel, Nan Jiang, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert, Jing Zhang, Qiang Zhang
  • Patent number: 9580411
    Abstract: The invention is concerned with the compounds of formula (I): and salts thereof, wherein X, Y, Z, R1, R2, R3, R3?, R4, R5 and R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of Formula (I) as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: February 28, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Huifen Chen, Shaoqing Chen, Zhi Chen, Shawn David Erickson, Anthony Estrada, Kyungjin Kim, Hongju Li, Allen John Lovey, Joseph P. Lyssikatos, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
  • Patent number: 9511059
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: December 6, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Qingjie Ding, Shawn David Erickson, Eric Mertz, Robert James Weikert
  • Patent number: 9394304
    Abstract: The invention is concerned with a compound of formula (I) wherein R1, R2, R2?, R3, R3? are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: July 19, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Stephan Bachmann, Shawn David Erickson, Dramane Ibrahim Laine, Yimin Qian
  • Patent number: 9388172
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    Type: Grant
    Filed: May 8, 2015
    Date of Patent: July 12, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Shawn David Erickson, Hongju Li, Sung-Sau So
  • Patent number: 9388166
    Abstract: The invention is concerned with the compounds of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) can be used as medicament.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: July 12, 2016
    Assignee: Hoffman-La Roche Inc.
    Inventors: Zhi Chen, Shawn David Erickson
  • Patent number: 9359337
    Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: May 14, 2015
    Date of Patent: June 7, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Yimin Qian
  • Patent number: 9353096
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    Type: Grant
    Filed: April 10, 2015
    Date of Patent: May 31, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi
  • Patent number: 9296711
    Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: March 29, 2016
    Assignee: HOFFMAN-LA ROCHE INC.
    Inventors: Shawn David Erickson, Paul Gillespie, Eric Mertz
  • Patent number: 9290465
    Abstract: The invention is concerned with a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Grant
    Filed: November 29, 2013
    Date of Patent: March 22, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: JohnMark Derryberry, Shawn David Erickson, Paul Gillespie, Eric Mertz
  • Publication number: 20160000760
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Application
    Filed: March 3, 2014
    Publication date: January 7, 2016
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Feng Chi, Elbert Chin, Qingjie Ding, Shawn David Erickson, Stephen Deems Gabriel, Nan Jiang, Buelent Kocer, Eric Mertz, Jean-Marc Plancher, Robert J. Weikert, Jing Zhang, Qiang Zhang
  • Publication number: 20150376165
    Abstract: The present invention discloses compounds of Formula I wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Application
    Filed: March 3, 2014
    Publication date: December 31, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Zhi Chen, Elbert Chin, Shawn David Erickson, Stephen Deems Gabriel, Eric Mertz, Robert James Weikert
  • Publication number: 20150353511
    Abstract: The present invention discloses compounds of Formula I: wherein the variables in Formula I are defined as described herein. Also disclosed are pharmaceutical compositions containing such compounds and methods for using the compounds of Formula I in the prevention or treatment of HCV infection.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 10, 2015
    Inventors: Joseph Anthony Bilotta, Zhi Chen, Qingjie Ding, Shawn David Erickson, Eric Mertz, Robert James Weikert
  • Publication number: 20150315160
    Abstract: The invention is concerned with a compound of formula (I) wherein R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: November 29, 2013
    Publication date: November 5, 2015
    Inventors: JohnMark Derryberry, Shawn David Erickson, Paul Gillespie, Eric Mertz
  • Publication number: 20150307463
    Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compound of formula (I) as well as pharmaceutical compositions containing such compounds. The compound of formula (I) are SCD1 inhibitors and may be useful in treating cancer.
    Type: Application
    Filed: December 2, 2013
    Publication date: October 29, 2015
    Inventors: Shawn David Erickson, Paul Gillespie, Eric Mertz
  • Publication number: 20150246918
    Abstract: The invention is concerned with a compound of formula (I) wherein R1, R2, R2?, R3, R3? are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: STEPHAN BACKMANN, SHAWN DAVID ERICKSON, DRAMANE IBRAHIM LAINE, YIMIN QIAN
  • Publication number: 20150246906
    Abstract: The invention is concerned with a compound of formula (I) and pharmaceutically acceptable salts thereof wherein R1 to R3, X and Y are as defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.
    Type: Application
    Filed: May 14, 2015
    Publication date: September 3, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: CHRISTINE E. BROTHERTON-PLEISS, ZHI CHEN, SHAWN DAVID ERICKSON, YIMIN QIAN
  • Publication number: 20150239873
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    Type: Application
    Filed: May 8, 2015
    Publication date: August 27, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: CHRISTINE E. BROTHERTON-PLEISS, SHAWN DAVID ERICKSON, HONGJU LI, SUNG-SAU SO
  • Publication number: 20150218144
    Abstract: The invention is concerned with the compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein Y, R1, R2 and R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula (I) as well as pharmaceutical compositions containing such compounds. The compounds of formula (I) are antagonists of the TRPA1 channel and may be useful in treating inflammatory diseases and disorders associated with that channel.
    Type: Application
    Filed: April 10, 2015
    Publication date: August 6, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christine E. Brotherton-Pleiss, Zhi Chen, Shawn David Erickson, Kyungjin Kim, Hongju Li, Yimin Qian, Sung-Sau So, Peter Michael Wovkulich, Lin Yi